ArticleFrontiers in tuberculosis2024
Article in Frontiers in tuberculosis, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- NTM-host matched infection models for the classification of drug efficacy against rapid and slow growing nontuberculous mycobacteria species.Scientific reports · 2026Article
- Immunopathological outcomes are isolate dependent in chronic Mycobacterium avium complex pulmonary disease.Disease models & mechanisms · 2026Article
- Effect of biofilm formation on the antimicrobial activity of tigecycline againstFrontiers in microbiology · 2026Article
- Characterization of new mouse models of acute and chronicAntimicrobial agents and chemotherapy · 2025Article
- Animal models of Mycobacterium abscessus pulmonary infection phenotypes: What are we modeling?PLoS pathogens · 2025Article
- C3HeB/FeJ mice with chronicMycobacteria (London, England) · 2025Article
- Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: Current practices and recommendations.Tuberculosis (Edinburgh, Scotland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Introduction: Chronic pulmonary infection with Methods: Mice received an intrapulmonary aerosol of Results: Endpoint CFU data in the lung and spleen showed that there was no significant difference in bacterial clearance between βENaC and WT mice. WBP data showed an impairment in overall respiratory function during and after Discussion: Even with CF-like features, the βENaC transgenic mice cleared
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.